![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 28, 19310-19319, July 14, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1

2
From the
University of California-Davis Cancer Center, Sacramento, California 95817 and the
Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037
Mucins provide a protective barrier for epithelial surfaces, and their overexpression in tumors has been implicated in malignancy. We have previously demonstrated that Muc4, a transmembrane mucin that promotes tumor growth and metastasis, physically interacts with the ErbB2 receptor tyrosine kinase and augments receptor tyrosine phosphorylation in response to the neuregulin-1
(NRG1
) growth factor. In the present study we demonstrate that Muc4 expression in A375 human melanoma cells, as well as MCF7 and T47D human breast cancer cells, enhances NRG1
signaling through the phosphatidylinositol 3-kinase pathway. In examining the mechanism underlying Muc4-potetiated ErbB2 signaling, we found that Muc4 expression markedly augments NRG1
binding to A375 cells without altering the total quantity of receptors expressed by the cells. Cell-surface protein biotinylation experiments and immunofluorescence studies suggest that Muc4 induces the relocalization of the ErbB2 and ErbB3 receptors from intracellular compartments to the plasma membrane. Moreover, Muc4 interferes with the accumulation of surface receptors within internal compartments following NRG1
treatment by suppressing the efficiency of receptor internalization. These observations suggest that transmembrane mucins can modulate receptor tyrosine kinase signaling by influencing receptor localization and trafficking and contribute to our understanding of the mechanisms by which mucins contribute to tumor growth and progression.
Received for publication, April 5, 2006 , and in revised form, May 9, 2006.
* This work was supported in part by California Breast Cancer Research Program Grant 7KB-0085 (to C .S.) and National Institutes of Health Grant GM068994 (to K. L. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by a California Breast Cancer Research Program supplemental award (Grant 7KB-0085S).
2 To whom correspondence should be addressed: University of California-Davis Cancer Center, Research Bldg. III, Rm. 1400, 4645 2nd Ave., Sacramento, CA 95817. Tel.: 916-734-0726; Fax: 916-734-0190; E-mail: klcarraway{at}ucdavis.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
E. H. Budi, L. B. Patterson, and D. M. Parichy Embryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formation Development, August 1, 2008; 135(15): 2603 - 2614. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chaturvedi, A. P. Singh, and S. K. Batra Structure, evolution, and biology of the MUC4 mucin FASEB J, April 1, 2008; 22(4): 966 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. C. Carraway and K. L. Carraway Sequestration and Segregation of Receptor Kinases in Epithelial Cells: Implications for ErbB2 Oncogenesis Sci. Signal., April 10, 2007; 2007(381): re3 - re3. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Cao, X. Wu, L. Yen, C. Sweeney, and K. L. Carraway III Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1 Mol. Cell. Biol., March 15, 2007; 27(6): 2180 - 2188. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Singh, P. Chaturvedi, and S. K. Batra Emerging Roles of MUC4 in Cancer: A Novel Target for Diagnosis and Therapy Cancer Res., January 15, 2007; 67(2): 433 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Tian and K. G. T. Hagen A UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase Is Required for Epithelial Tube Formation J. Biol. Chem., January 5, 2007; 282(1): 606 - 614. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |